Profile
| Metric | Value |
|---|---|
| Full Name | Revolution Medicines, Inc. |
| Ticker | NASDAQ: RVMD |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United States |
| IPO | |
| Indexes | Not included |
| Website | revmed.com |
| Employees | 616 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $121.22 | |
| Price, 1D Change | +1.06% | |
| Market Cap | $23B | |
| - | ||
| PE Ratio | - | |
| Beta | 1.03 | |
| Revenue | $0 | |
| Revenue, 1Y Change | -100.00% | |
| EPS | -$3.58 | |
| EPS, 1Y Change | +7.23% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | -$3.58 | |
| EPS Estimate | -$5.54 | |
| EPS Est. Change | -54.88% | |
| Revenue | $0.00 | |
| Revenue Estimate | $3.68M | |
| Revenue Est. Change | - | |
| Current Price | $121.22 | |
| Price Target | - | $86.50 |
| Price Tgt. Change | - | -28.64% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| -$3.47 | -$3.86 | -11.14% | |
| -$3.43 | -$3.58 | -4.21% | |
| -$5.54 | N/A | -54.88% | |
| -$6.29 | N/A | -75.68% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $11.94M | $11.58M | -3.02% | |
| $346.15K | $0.00 | -100.00% | |
| $3.68M | N/A | - | |
| $31.84M | N/A | - |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +204.34% | |
| Price, 3Y | +302.86% | |
| Market Cap, 1Y | +216.50% | |
| Market Cap, 3Y | +761.40% | |
| Revenue, 1Y | -100.00% | |
| Revenue, 3Y | -100.00% | |
| EPS, 1Y | +7.23% | |
| EPS, 3Y | -39.22% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $121.22 | |
| SMA 200 | $50.22 | |
| SMA 200 vs Price | -58.57% | |
| SMA 50 | $78.72 | |
| SMA 50 vs Price | -35.06% | |
| Beta | 1.03 | |
| ATR | $5.41 | |
| 14-Day RSI | 89.27 | |
| 10-Day Volatility | 145.02% | |
| 1-Year Volatility | 53.45% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| Dividends Paid | $0.00 | |
| Payout Ratio | 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $0.00 | |
| EPS | -$3.58 | |
| Gross Profit | -$11.82M | |
| Gross Margin | - | |
| Operating Profit | -$689.52M | |
| Operating Margin | - | |
| Net Income | -$600.09M | |
| Net Margin | - | |
| EBITDA | -$677.70M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 0.06 | |
| Current Ratio | 14.20 | |
| Quick Ratio | 14.20 | |
| - | ||
| F-Score | - | |
| Altman Z-Score | 40.76 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | - | |
| PS Ratio | - | |
| PB Ratio | 14.67 | |
| EV/EBITDA | -21.20 | |
| Enterprise Value | N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $2.27B | |
| Cash & Equivalents | $543.06M | |
| Total Assets | $2.60B | |
| Current Assets | $2.33B | |
| Total Liabilities | $338.20M | |
| Current Liabilities | $163.91M | |
| Total Debt | $135.84M | |
| Short Term Debt | $12.87M | |
| Accounts Payable | $54.43M |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | $689.52M | |
| Operating Expenses | $689.52M | |
| Cost Of Goods Sold | $11.82M | |
| SG&A | $97.30M | |
| D&A | $11.82M | |
| Interest Expense | $0.00 | |
| Income Tax | -$753.00K |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | -$557.44M | |
| CFI | -$554.39M | |
| CFF | $959.41M | |
| Capex | $10.31M | |
| Free Cash Flow | -$567.74M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Wolfe Research | ||
| Wedbush | → | |
| Needham | → | |
| JP Morgan | → | |
| HC Wainwright & Co. | → | |
| RBC Capital | ||
| Mizuho | ||
| Wedbush | → | |
| Raymond James | → | |
| Goldman Sachs | → |
Analyst sentiment
Institutional ownership
Screeners with RVMD
Data Sources & References
- RVMD Official Website www.revmed.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/1628171/000119312525266923/0001193125-25-266923-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1628171/000095017025027736/0000950170-25-027736-index.htm
- RVMD Profile on Yahoo Finance finance.yahoo.com/quote/RVMD
- RVMD Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/rvmd
FAQ
What is the ticker symbol for Revolution Medicines, Inc.?
The ticker symbol for Revolution Medicines, Inc. is NASDAQ:RVMD
Does Revolution Medicines, Inc. pay dividends?
No, Revolution Medicines, Inc. does not pay dividends
What sector is Revolution Medicines, Inc. in?
Revolution Medicines, Inc. is in the Healthcare sector
What industry is Revolution Medicines, Inc. in?
Revolution Medicines, Inc. is in the Biotechnology industry
What country is Revolution Medicines, Inc. based in?
Revolution Medicines, Inc. is headquartered in United States
When did Revolution Medicines, Inc. go public?
Revolution Medicines, Inc. initial public offering (IPO) was on February 13, 2020
Is Revolution Medicines, Inc. in the S&P 500?
No, Revolution Medicines, Inc. is not included in the S&P 500 index
Is Revolution Medicines, Inc. in the NASDAQ 100?
No, Revolution Medicines, Inc. is not included in the NASDAQ 100 index
Is Revolution Medicines, Inc. in the Dow Jones?
No, Revolution Medicines, Inc. is not included in the Dow Jones index
When was Revolution Medicines, Inc. last earnings report?
Revolution Medicines, Inc.'s most recent earnings report was on November 5, 2025
When does Revolution Medicines, Inc. report earnings?
The next expected earnings date for Revolution Medicines, Inc. is February 25, 2026